Stock Analysis
Data Source: SEC EDGAR 13F
Updated Hourly

Guardant Health Inc (GH)

583 + Investors. Track Smart Money conviction in GH. See who's accumulating, reducing, or initiating positions.

Current Price
-- USD
Analyst Target
-- (0 analysts)
Upside
0.00%
Net Flow Q/Q
↑ +107
Streak
1Q ▲
Buyers last Q
60%

Smart Money Signals — GH

Based on 592 hedge funds · latest filing: 2026 Q2 · updated quarterly

📈

Buying streak — 1 quarter in a row

last 6Q
For 1 consecutive quarter, more hedge funds added GH than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.
🏔️

At the ownership peak (100% of max)

100% of all-time peak
592 hedge funds hold GH right now — the highest count in 3.0 years. When ownership is this concentrated, any bad news can trigger a chain reaction: one big fund sells, others follow. This is a classic 'crowded trade' — high popularity doesn't equal safety.
🚀

Fast accumulation — +64% more funds vs a year ago

fund count last 6Q
+230 new funds entered over the past year (+64% YoY). That's a rapid rush of institutional money. Fast accumulation often signals a major thesis — but it also means the stock could fall quickly if that thesis breaks.
🟢

More buyers than sellers — 60% buying

352 buying239 selling
Last quarter: 352 funds were net buyers (157 opened a brand new position + 195 added to an existing one). Only 239 were sellers (189 trimmed + 50 sold completely). A clear majority buying is a strong confirmation signal.
📈

More new buyers each quarter (+82 vs last Q)

new funds entering per quarter
Funds opening a new GH position: 69 → 142 → 75 → 157. A growing influx of new institutional buyers means the asset is still gathering momentum — the consensus hasn't fully saturated yet.
🔒

45% of holders stayed for 2+ years

■ 45% conviction (2yr+) ■ 22% medium ■ 33% new
266 out of 592 hedge funds have held GH for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.
💰

Value +58% but shares only +10% — price-driven

Value
+57%
Shares
+9%
Last quarter: the total dollar value of institutional holdings rose +58%, but actual share count only changed +10%. The gap is explained by the stock's price rising — not new buying. Strong value growth with weak share growth means the rally is price momentum, not fresh institutional demand.
➡️

Steady discovery — ~157 new funds/quarter

68 → 69 → 142 → 75 → 157 new funds/Q
New funds entering each quarter: 69 → 142 → 75 → 157. Consistent flow of new institutional buyers without clear acceleration or slowdown.
🏛️

Veteran-anchored — 57% veterans vs 35% newcomers

■ 57% veterans ■ 8% 1-2yr ■ 35% new
Entry-cohort mix of 614 holders: 349 (57%) are 2+ year veterans, 52 entered 1–2 years ago, and 213 (35%) joined within the past year. A veteran-weighted cap table skews toward institutional memory over fresh momentum.
🏆

Elite ownership — 52% AUM from top-100 funds

52% from top-100 AUM funds
66 of 589 holders are among the 100 largest funds by AUM, controlling 52% of total institutional value in GH. When the biggest players dominate the cap table, it signifies deep institutional support — since mega-funds deploy the most rigorous due diligence and capital.
4.4
out of 10
Moderate Exit Risk
Exit risk score 4.4/10 — some crowding factors present, but no critical concentration. Watch ownership trend over the next 1–2 quarters for direction.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Institutional Sentiment Summary — GH

In 2026 Q2, 352 hedge funds were net buyers of GH (157 opened a new position, 195 added to an existing one), while 239 reduced or exited (189 trimmed, 50 sold completely) — a 60% buyer ratio, indicating clear institutional accumulation. 52% of total institutional value in GH is held by top-100 AUM funds, reflecting elite-tier ownership quality. Net fund flow last quarter: +107 funds (more new holders than closures). Total institutional holders: 592.

Hedge Fund Ownership: GH

How many hedge funds hold GH — quarterly history vs. share price
Quarterly hedge fund ownership of GH vs. share price

Market Analysis: GH

Analyst Price Targets

Avg. Price Target
--

Analyst Recommendations

Stock Performance

Real-time

Company Profile: GH

-- --

Institutional ownership data sourced from SEC EDGAR Form 13F-HR filings.

Is It Too Late to Buy Guardant Health Inc (GH) Based on Hedge Fund 13F Filings?

Signal Freshness measures how much GH has moved relative to its sector benchmark (XLV) since the 2026 Q2 13F filing. A stock that has barely outrun its sector is still a relatively fresh entry point — the fund's thesis has not yet been priced in by the broader market.

Since Quarter End June 30, 2026 · 90d ago
GH
+18.7%
XLV
+8.2%

GH outperformed XLV by +10.5% since June 30, 2026.

Since 13F Filing Date August 14, 2026 · 45d ago
GH
+13.3%
XLV
+2.5%

Since the filing became public, GH outperformed XLV by +10.8% .

Interpretation: The stock has meaningfully outrun its sector. The trade has partially played out; entry is at a premium to the fund's implied reference. Learn more →

Smart Money Signal ?
Limited Smart Money Interest

No strong consensus or elite conviction detected among institutional holders.

24 top-rated funds 6 high-conviction
Consensus
6.1
/ 10
breadth
×
Elite
4.4
/ 10
conviction
Hedge Fund Positioning: GH
583 + Investors

Track Smart Money conviction in GH. See who's accumulating, reducing, or initiating positions.

Metric All 13F Filers (2026 Q2) Prior (2026 Q1) Change
Funds Holding 583 485 20.21%
13F Shares 135M 142M -5.28%
Total Value $18.78B $11.99B 56.66%
New Positions 153 75 +78
Increased Positions 191 188 +3
Closed Positions 52 83 -31
Reduced Positions 181 159 +22
Total Calls 11 10 10.0%
Total Puts 14 12 16.67%
PUT/CALL Ratio 1.27 1.2 Bearish

Statistics: GH

View More

Valuation Measures Data as of: --

Market Cap --
Enterprise Value --
Trailing P/E --
Forward P/E --
PEG Ratio (5yr expected) --
Price/Sales (ttm) --
Price/Book (mrq) --
Enterprise Value/Revenue --
Enterprise Value/EBITDA --
Beta (5Y Monthly) --
Short Ratio (Days to Cover) --
Short % of Float --

Financial Highlights

Profitability
Profit Margin --
Return on Assets (ttm) --
Return on Equity (ttm) --
Income Statement & Cash Flow
Revenue (ttm) --
Net Income Avi to Common (ttm) --
Diluted EPS (ttm) --
Total Cash (mrq) --
Total Debt/Equity (mrq) --
Levered Free Cash Flow (ttm) --

Institutional Holders (2026 Q2)

583 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in GH. Verified SEC 13F-HR filings.

QUARTER:
Top 25 GH holders by conviction (% of portfolio weight) — 2026 Q2 · Source: SEC Form 13F
# Investor % of Portfolio Shares Mkt Value
1 Blue Water Life Science Advisors, LP 10.84% 114,747 $17.2M
2 Cadian Capital Management, LP 8.60% 757,393 $113.6M
3 Sicart Associates LLC 8.49% 231,015 $34.7M
4 Eagle Health Investments LP 7.48% 300,685 $45.1M
5 Deep Track Capital, LP 7.41% 3,393,312 $509.1M
6 Exome Asset Management LLC 6.25% 67,500 $10.1M
7 Science & Technology Partners, L.P. 5.28% 208,817 $31.3M
8 First Light Asset Management, LLC 4.03% 441,586 $66.3M
9 Adalta Capital Management LLC 3.97% 60,310 $9.0M
10 Eventide Asset Management, LLC 3.93% 1,957,828 $293.8M
11 Lagoda Investment Management, L.P. 3.08% 37,365 $5.6M
12 Future Fund LLC 2.76% 64,237 $9.6M
13 Aristotle Atlantic Partners, LLC 2.75% 442,816 $66.4M
14 Summit Partners Public Asset Management, LLC 2.55% 967,697 $145.2M
15 SWS Partners 2.42% 74,582 $11.2M
16 Rtw Investments, LP 1.90% 1,481,033 $222.2M
17 Atika Capital Management LLC 1.78% 181,000 $27.2M
18 Rhenman & Partners Asset Management AB 1.63% 115,000 $17.3M
19 Orbimed Advisors LLC 1.62% 583,700 $87.6M
20 Morgens Waterfall Vintiadis & Co Inc 1.60% 14,000 $2.1M
21 Next Century Growth Investors LLC 1.60% 200,672 $30.1M
22 Silverarc Capital Management, LLC 1.56% 99,826 $15.0M
23 Revere Asset Management, Inc 1.53% 26,620 $4.0M
24 Hood River Capital Management LLC 1.52% 1,395,307 $209.3M
25 Emerald Mutual Fund Advisers Trust 1.43% 271,380 $40.7M
Investor Ownership
History 		% of Portfolio Prev % Rank Conviction Avg Buy Price 13F Score™ 3Y / 7Y Sell Timing Shares Mkt Value Change Change % Source Quarter Filed

Frequently Asked Questions — Guardant Health Inc (GH)

What does the Smart Money Trend signal show for GH?

Buying streak — 1 quarter in a row: For 1 consecutive quarter, more hedge funds added GH than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

What is the institutional breadth score for GH?

More buyers than sellers — 60% buying: Last quarter: 352 funds were net buyers (157 opened a brand new position + 195 added to an existing one). Only 239 were sellers (189 trimmed + 50 sold completely). A clear majority buying is a strong confirmation signal.

What is the fund quality score for GH holders?

Elite ownership — 52% AUM from top-100 funds: 66 of 589 holders are among the 100 largest funds by AUM, controlling 52% of total institutional value in GH. When the biggest players dominate the cap table, it signifies deep institutional support — since mega-funds deploy the most rigorous due diligence and capital.

How long have hedge funds held GH?

45% of holders stayed for 2+ years: 266 out of 592 hedge funds have held GH for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.

Is it too late to buy Guardant Health Inc (GH) following the 2026 Q2 hedge fund 13F filings?

As of today, GH has moved +13.3% since the 2026 Q2 13F filing date (August 14, 2026), compared to +2.5% for the XLV sector ETF — an outperformance of +10.8%. Since the quarter end (June 30, 2026), GH has gained +18.7% vs +8.2% for XLV. The stock has meaningfully outrun its sector. The trade has partially played out; entry is at a premium to the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Disclaimer: The information on this page is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Institutional holdings data is sourced from SEC Form 13F filings and reflects positions as of the filing date. Past performance of any fund or portfolio is not indicative of future results. 13Foresight is not a registered investment adviser. Always conduct your own due diligence before making investment decisions.

Full history →